000513 Stock Overview
Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥38.03 |
| 52 Week High | CN¥44.72 |
| 52 Week Low | CN¥32.70 |
| Beta | 0.28 |
| 11 Month Change | -1.81% |
| 3 Month Change | 6.98% |
| 1 Year Change | 9.98% |
| 33 Year Change | 3.29% |
| 5 Year Change | 18.29% |
| Change since IPO | 3,745.32% |
Recent News & Updates
Recent updates
We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings
Aug 30
Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 26A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)
Aug 09Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year
Jul 02We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right
Jun 07Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Apr 26Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?
Apr 21Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?
Mar 15Shareholder Returns
| 000513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.9% | -1.3% | -3.4% |
| 1Y | 10.0% | -3.4% | 6.1% |
Return vs Industry: 000513 exceeded the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 000513 exceeded the CN Market which returned 6.1% over the past year.
Price Volatility
| 000513 volatility | |
|---|---|
| 000513 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 000513 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000513's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 8,920 | Yanggang Tang | www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
| 000513 fundamental statistics | |
|---|---|
| Market cap | CN¥30.74b |
| Earnings (TTM) | CN¥2.02b |
| Revenue (TTM) | CN¥11.86b |
17.2x
P/E Ratio2.9x
P/S RatioIs 000513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000513 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.86b |
| Cost of Revenue | CN¥4.39b |
| Gross Profit | CN¥7.46b |
| Other Expenses | CN¥5.44b |
| Earnings | CN¥2.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.21 |
| Gross Margin | 62.94% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 27.4% |
How did 000513 perform over the long term?
See historical performance and comparison